In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after ...
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results